Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ISPR
ISPR logo

ISPR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Ispire Technology Inc (ISPR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.210
1 Day change
-10.00%
52 Week Range
4.700
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Ispire Technology Inc (ISPR) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators show a bearish trend, the financial performance is weak, and there are no positive catalysts or significant trading signals to suggest immediate upside potential. Holding off for now is recommended.

Technical Analysis

The MACD is negative and expanding (-0.0898), indicating a bearish trend. RSI is at 20.18, suggesting the stock is approaching oversold territory but not yet a clear buy signal. Moving averages are converging, showing no clear direction. The stock is trading near its support level (S1: 1.917), with resistance at R1: 2.567.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
2

Positive Catalysts

  • NULL. No recent news, no significant hedge fund or insider activity, and no congress trading data.

Neutral/Negative Catalysts

  • Weak financial performance in Q2 2026, with revenue down -51.50% YoY, net income down -17.45% YoY, and EPS down -14.29% YoY. Gross margin also dropped to 17.13%. Technical indicators suggest a bearish trend.

Financial Performance

In Q2 2026, revenue dropped to $20,286,556 (-51.50% YoY), net income dropped to -$6,602,911 (-17.45% YoY), and EPS dropped to -0.12 (-14.29% YoY). Gross margin declined to 17.13% (-7.20% YoY). Overall, the company is showing significant financial weakness.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available for ISPR.

Wall Street analysts forecast ISPR stock price to rise
1 Analyst Rating
Wall Street analysts forecast ISPR stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.450
sliders
Low
6.5
Averages
6.5
High
6.5
Current: 2.450
sliders
Low
6.5
Averages
6.5
High
6.5
Roth Capital
Buy
downgrade
$9
AI Analysis
2025-05-15
Reason
Roth Capital
Price Target
$9
AI Analysis
2025-05-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Ispire Technology to $7.50 from $9 and keeps a Buy rating on the shares. The company's Q2 results were "tempered" as shipment timing on its U.K. supply agreement is being pushed into fiscal Q4 and given that Chinese New Year seasonality and tariffs are also impacting order timing, the analyst tells investors in a research note. An FDA decision in the coming months should provide greater future visibility around licensing opportunities, the firm adds.
Roth MKM
Nick Anderson
Strong Buy
Reiterates
$9
2025-03-20
Reason
Roth MKM
Nick Anderson
Price Target
$9
2025-03-20
Reiterates
Strong Buy
Reason

People Also Watch